

TOXICOLOGICAL PROFILE FOR
ANTIMONY AND COMPOUNDS

Agency for Toxic Substances and Disease Registry
U.S. Public Health Service

September 1992

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

FOREWORD

The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) extended and amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances which are most commonly found at facilities on the CERCLA National Priorities List and which pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The lists of the 250 most significant hazardous substances were published in the Federal Register on April 17, 1987; on October 20, 1988; on October 26, 1989; and on October 17, 1990. A revised list of 275 substances was published on October 17, 1991.

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the lists. Each profile must include the following content:

- (A) An examination, summary, and interpretation of available toxicological information and epidemiological evaluations on the hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure which present a significant risk to human health of acute, subacute, and chronic health effects.
- (C) Where appropriate, an identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile is intended to characterize succinctly the toxicological and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Foreword

Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health will be identified by ATSDR, the National Toxicology Program (NTP) of the Public Health Service, and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control, the NTP, and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



William L. Roper, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

CONTENTS

FOREWORD	iii
LIST OF FIGURES	ix
LIST OF TABLES	xi
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS ANTIMONY?	1
1.2 HOW MIGHT I BE EXPOSED TO ANTIMONY?	2
1.3 HOW CAN ANTIMONY ENTER AND LEAVE MY BODY?	3
1.4 HOW CAN ANTIMONY AFFECT MY HEALTH?	4
1.5 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO ANTIMONY?	4
1.6 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	5
1.7 WHERE CAN I GET MORE INFORMATION?	5
2. HEALTH EFFECTS	7
2.1 INTRODUCTION	7
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	7
2.2.1 Inhalation Exposure	8
2.2.1.1 Death	8
2.2.1.2 Systemic Effects	15
2.2.1.3 Immunological Effects	19
2.2.1.4 Neurological Effects	19
2.2.1.5 Developmental Effects	19
2.2.1.6 Reproductive Effects	19
2.2.1.7 Genotoxic Effects	20
2.2.1.8 Cancer	20
2.2.2 Oral Exposure	20
2.2.2.1 Death	20
2.2.2.2 Systemic Effects	21
2.2.2.3 Immunological Effects	26
2.2.2.4 Neurological Effects	26
2.2.2.5 Developmental Effects	27
2.2.2.6 Reproductive Effects	27
2.2.2.7 Genotoxic Effects	27
2.2.2.8 Cancer	27
2.2.3 Dermal Exposure	28
2.2.3.1 Death	28
2.2.3.2 Systemic Effects	28
2.2.3.3 Immunological Effects	31
2.2.3.4 Neurological Effects	31
2.2.3.5 Developmental Effects	31
2.2.3.6 Reproductive Effects	31
2.2.3.7 Genotoxic Effects	31
2.2.3.8 Cancer	32

2.3	TOXICOKINETICS	32
2.3.1	Absorption	32
2.3.1.1	Inhalation Exposure	32
2.3.1.2	Oral Exposure	32
2.3.1.3	Dermal Exposure	33
2.3.2	Distribution	33
2.3.2.1	Inhalation Exposure	33
2.3.2.2	Oral Exposure	35
2.3.2.3	Dermal Exposure	35
2.3.2.4	Other Routes of Exposure	35
2.3.3	Metabolism	36
2.3.4	Excretion	36
2.3.4.1	Inhalation Exposure	36
2.3.4.2	Oral Exposure	36
2.3.4.3	Dermal Exposure	37
2.3.4.4	Other Routes of Exposure	37
2.4	RELEVANCE TO PUBLIC HEALTH	38
2.5	BIOMARKERS OF EXPOSURE AND EFFECT	45
2.5.1	Biomarkers Used to Identify and/or Quantify Exposure to Antimony	46
2.5.2	Biomarkers Used to Characterize Effects Caused by Antimony	46
2.6	INTERACTIONS WITH OTHER CHEMICALS	46
2.7	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	46
2.8	MITIGATION OF EFFECTS	46
2.9	ADEQUACY OF THE DATABASE	47
2.9.1	Existing Information on Health Effects of Antimony	48
2.9.2	Data Needs	50
2.9.3	On-going Studies	55
3.	CHEMICAL AND PHYSICAL INFORMATION	57
3.1	CHEMICAL IDENTITY	57
3.2	PHYSICAL AND CHEMICAL PROPERTIES	57
4.	PRODUCTION, IMPORT, USE, AND DISPOSAL	63
4.1	PRODUCTION	63
4.2	IMPORT/EXPORT	67
4.3	USE	67
4.4	DISPOSAL	68
5.	POTENTIAL FOR HUMAN EXPOSURE	69
5.1	OVERVIEW	69
5.2	RELEASES TO THE ENVIRONMENT	74
5.2.1	Air	74
5.2.2	Water	77
5.2.3	Soil	78

5.3	ENVIRONMENTAL FATE	78
5.3.1	Transport and Partitioning	78
5.3.2	Transformation and Degradation	82
5.3.2.1	Air	82
5.3.2.2	Water	82
5.3.2.3	Soil	86
5.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	87
5.4.1	Air	87
5.4.2	Water	89
5.4.3	Soil	91
5.4.4	Other Environmental Media	92
5.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	93
5.6	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	96
5.7	ADEQUACY OF THE DATABASE	97
5.7.1	Data Needs	97
5.7.2	On-going Studies	100
6.	ANALYTICAL METHODS	101
6.1	BIOLOGICAL MATERIALS	101
6.2	ENVIRONMENTAL SAMPLES	102
6.3	ADEQUACY OF THE DATABASE	106
6.3.1	Data Needs	106
6.3.2	On-going Studies	107
7.	REGULATIONS AND ADVISORIES	109
8.	REFERENCES	113
9.	GLOSSARY	133
APPENDICES		
A.	USER'S GUIDE	A-1
B.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS	B-1
C.	PEER REVIEW	C-1

LIST OF FIGURES

2-1	Levels of Significant Exposure to Antimony - Inhalation	13
2-2	Levels of Significant Exposure to Antimony - Oral	25
2-3	Existing Information on Health Effects of Antimony	49
5-1	Frequency of NPL Sites with Antimony Contamination	73

LIST OF TABLES

2-1	Levels of Significant Exposure to Antimony - Inhalation	9
2-2	Levels of Significant Exposure to Antimony - Oral	22
2-3	Levels of Significant Exposure to Antimony - Dermal	29
2-4	Levels of Antimony Found in Various Tissues of Unexposed Humans . .	34
2-5	Genotoxicity of Antimony <u>In Vitro</u>	44
3-1	Chemical Identity of Antimony and Compounds	58
3-2	Physical and Chemical Properties of Antimony and Compounds	60
4-1	Facilities that Manufacture, Process, or Use Antimony and Compounds	65
5-1	Releases to the Environment from Facilities That Manufacture, Process, or use Antimony and Compounds	70
6-1	Analytical Methods for Determining Antimony in Biological Materials	103
6-2	Analytical Methods for Determining Antimony in Environmental Samples	105
7-1	Regulations and Guidelines Applicable to Antimony and Compounds	110

